Editas Medicine, Inc.

Symbol: EDIT




Market price today

  • -3.5903

    P/E Ratio

  • 0.0278

    PEG Ratio

  • 538.33M

    MRK Cap

  • 0.00%

    DIV Yield

Editas Medicine, Inc. (EDIT) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Gilmore O'Neill M.D.
Full-time employees:265
Address:11 Hurley Street

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

General Outlook

In simple terms, Editas Medicine, Inc. has 81.814 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.922% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -2.100%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -1.917%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.300% return, is a testament to Editas Medicine, Inc.'s adeptness in optimizing resource deployment. Editas Medicine, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.420%. Furthermore, the proficiency of Editas Medicine, Inc. in capital utilization is underscored by a remarkable -0.376% return on capital employed.

Stock Prices

Editas Medicine, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $7.41, while its low point bottomed out at $7.15. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Editas Medicine, Inc.'s stock market.

Liquidity Ratios

Analyzing EDIT liquidity ratios reveals its financial health of the firm. The current ratio of 539.14% gauges short-term asset coverage for liabilities. The quick ratio (527.23%) assesses immediate liquidity, while the cash ratio (195.60%) indicates cash reserves.

Current Ratio539.14%
Quick Ratio527.23%
Cash Ratio195.60%

Profitability Ratios

EDIT profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -196.13% underscores its earnings before tax deductions. The effective tax rate stands at 6.74%, revealing its tax efficiency. The net income per EBT, 97.74%, and the EBT per EBIT, 93.41%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -209.97%, we grasp its operational profitability.

Pretax Profit Margin-196.13%
Effective Tax Rate6.74%
Net Income per EBT97.74%
EBT per EBIT93.41%
EBIT per Revenue-209.97%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 5.39, it details the span from stock purchase to revenue. The 5 days it takes to settle debts showcases its creditor relations. Meanwhile, a 2 cash conversion cycle and 766.89% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding527
Operating Cycle47.59
Days of Payables Outstanding498
Cash Conversion Cycle-450
Receivables Turnover7.67
Payables Turnover0.73
Fixed Asset Turnover1.71
Asset Turnover0.16

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.62, and free cash flow per share, -1.68, depict cash generation on a per-share basis. The cash per share value, 3.95, showcases liquidity position. Lastly, the operating cash flow sales ratio, -1.69, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-1.62
Free Cash Flow per Share-1.68
Cash per Share3.95
Operating Cash Flow Sales Ratio-1.69
Free Cash Flow to Operating Cash Flow Ratio1.04
Cash Flow Coverage Ratio-3.62
Short Term Coverage Ratio-10.87
Capital Expenditure Coverage Ratio-28.01
Dividend Paid and Capex Coverage Ratio-28.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 7.32%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.10, we discern the balance between debt and equity financing. The long-term debt to capitalization, 6.53%, and total debt to capitalization, 9.47%, ratios shed light on its capital structure. An interest coverage of 47.29 indicates its ability to manage interest expenses.

Debt Ratio7.32%
Debt Equity Ratio0.10
Long Term Debt to Capitalization6.53%
Total Debt to Capitalization9.47%
Interest Coverage47.29
Cash Flow to Debt Ratio-3.62
Company Equity Multiplier1.43

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.03, provides a glimpse into top-line earnings distributed across each share. Net income per share, -2.02, reflects the portion of profit attributed to each share. The book value per share, 4.60, represents the net asset value distributed per share, while the tangible book value per share, 4.60, excludes intangible assets.

Revenue Per Share1.03
Net Income Per Share-2.02
Book Value Per Share4.60
Tangible Book Value Per Share4.60
Shareholders Equity Per Share4.60
Interest Debt Per Share0.48
Capex Per Share-0.06

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 296.32%, indicates top-line expansion, while the gross profit growth, 438.76%, reveals profitability trends. EBIT growth, 25.12%, and operating income growth, 25.12%, offer insights into operational profitability progression. The net income growth, 25.02%, showcases bottom-line expansion, and the EPS growth, 32.21%, measures the growth in earnings per share.

Revenue Growth296.32%
Gross Profit Growth438.76%
EBIT Growth25.12%
Operating Income Growth25.12%
Net Income Growth25.02%
EPS Growth32.21%
EPS Diluted Growth32.21%
Weighted Average Shares Growth10.63%
Weighted Average Shares Diluted Growth10.63%
Operating Cash Flow Growth25.47%
Free Cash Flow Growth24.56%
5-Year Revenue Growth per Share51.66%
3-Year Revenue Growth per Share-33.57%
5-Year Operating CF Growth per Share-79.29%
3-Year Operating CF Growth per Share43.30%
5-Year Net Income Growth per Share13.61%
3-Year Net Income Growth per Share-8.04%
5-Year Shareholders Equity Growth per Share-8.35%
3-Year Shareholders Equity Growth per Share-31.57%
5-Year Dividend per Share Growth per Share-100.00%
Receivables Growth98.00%
Inventory Growth100.00%
Asset Growth-2.95%
Book Value per Share Growth-12.51%
Debt Growth-16.86%
R&D Expense Growth-1.93%
SGA Expenses Growth-1.49%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 682,415,862.29, captures the company's total value, considering both debt and equity. Income quality, 0.86, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.89, gauges operational efficiency, while the research and development to revenue, 219.64%, highlights investment in innovation.

Enterprise Value682,415,862.29
Income Quality0.86
Sales General and Administrative to Revenue0.89
Research and Development to Revenue219.64%
Capex to Operating Cash Flow3.57%
Capex to Revenue-6.04%
Capex to Depreciation-77.82%
Stock-Based Compensation to Revenue25.34%
Graham Number14.44
Return on Tangible Assets-30.70%
Graham Net Net2.38
Working Capital277,612,000
Tangible Asset Value349,097,000
Net Current Asset Value190,773,000
Average Receivables7,666,000
Average Payables8,890,000
Average Inventory-46,548,500
Days Sales Outstanding48
Days Payables Outstanding498

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.54, and the price to book ratio, 1.54, reflect the market's valuation relative to the company's book value. The price to sales ratio, 6.89, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -3.93, and price to operating cash flows, -4.07, gauge market valuation against cash flow metrics.

Price Book Value Ratio1.54
Price to Book Ratio1.54
Price to Sales Ratio6.89
Price Cash Flow Ratio-4.07
Price Earnings to Growth Ratio0.03
Enterprise Value Multiple-3.85
Price Fair Value1.54
Price to Operating Cash Flow Ratio-4.07
Price to Free Cash Flows Ratio-3.93
Price to Tangible Book Ratio2.20
Enterprise Value to Sales8.74
Enterprise Value Over EBITDA-4.18
EV to Operating Cash Flow-5.16
Earnings Yield-19.91%
Free Cash Flow Yield-17.79%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Editas Medicine, Inc. (EDIT) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -3.590 in 2024.

What is the ticker symbol of Editas Medicine, Inc. stock?

The ticker symbol of Editas Medicine, Inc. stock is EDIT.

What is company IPO date?

IPO date of Editas Medicine, Inc. is 2016-02-03.

What is company current share price?

Current share price is 6.580 USD.

What is stock market cap today?

The market cap of stock today is 538334804.000.

What is PEG ratio in 2024?

The current 0.028 is 0.028 in 2024.

What is the number of employees in 2024?

In 2024 the company has 265.